Inhaled treprostinil for the treatment of pulmonary arterial hypertension

Expert Review of Respiratory Medicine

Volumn 6, Issue 3, 2012, Pages 255-265

  Levarge, Barbara L ^a   Channick, Richard N ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

administration; analogs and derivatives; epoprostenol; inhalation; pulmonary arterial hypertension; pulmonary circulation; treprostinil

Indexed keywords

AMBRISENTAN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BOSENTAN; FRACTALKINE; ILOPROST; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACEBO; PROSTACYCLIN; RANTES; SILDENAFIL; TADALAFIL; UNIPROST;

AEROSOL; ANGIOGENESIS; BLEEDING; CARDIOPULMONARY HEMODYNAMICS; CELL PROLIFERATION; CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION; CONTINUOUS INFUSION; COUGHING; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STABILITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXERCISE; FEASIBILITY STUDY; FLUSHING; HEADACHE; HEART CATHETERIZATION; HEART OUTPUT; HEMOPTYSIS; HUMAN; HYPOTENSION; INFLAMMATION; LUNG BLOOD VESSEL; MORBIDITY; MORTALITY; NAUSEA; NONHUMAN; PH; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PULMONARY HYPERTENSION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ROOM TEMPERATURE; SIDE EFFECT; SINGLE DRUG DOSE; SMOOTH MUSCLE RELAXATION; SORE THROAT; THROAT IRRITATION; THROMBOCYTE AGGREGATION; TREATMENT DURATION; VASODILATATION;

EID: 84863886265     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.12.23     Document Type: Review

References (78)

1. Badesch DB, Champion HC, Sanchez MA et al. Diagnosis and assessment of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S55-S66 (2009
2. Simonneau G, Robbins IM, Beghetti M et al. Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S43-S54 (2009
3. Humbert M, Sitbon O, Chaouat A et al. Pulmonary arterial hypertension in France: Results from a national registry. Am. J. Respir. Crit. Care Med. 173(9), 1023-1030 (2006
4. D'Alonzo GE, Barst RJ, Ayres SM et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann. Intern. Med. 115(5), 343-349 (1991
5. Barst RJ, Rubin LJ, Long WA et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N. Engl. J. Med. 334(5), 296-302 (1996
6. Galiè N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-Analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J. 30(4), 394-403 (2009
7. Humbert M, Sitbon O, Yaici A et al.; French Pulmonary Arterial Hypertension Network. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur. Respir. J. 36(3), 549-555 (2010
8. Barst RJ, Gibbs JS, Ghofrani HA et al. Updated evidence-Based treatment algorithm in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S78-S84 (2009
9. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelinreceptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-Controlled study. Lancet 358(9288), 1119-1123 (2001
10. Galiè N, Ghofrani HA, Torbicki A et al.; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353(20), 2148-2157 (2005
11. Galiè N, Olschewski H, Oudiz RJ et al.; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-Blind, placebocontrolled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117(23), 3010-3019 (2008
12. Galiè N, Brundage BH, Ghofrani HA et al.; Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension. Circulation 119(22), 2894-2903 (2009
13. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur. Respir. J. 31(4), 891-901 (2008
14. Olschewski H, Rose F, Schermuly R et al. Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol. Ther. 102(2), 139-153 (2004
15. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-Term continuous intravenous prostacyclin. Ann. Intern. Med. 121(6), 409-415 (1994
16. Higenbottam TW, Spiegelhalter D, Scott JP et al. Prostacyclin (epoprostenol) and heart-Lung transplantation as treatments for severe pulmonary hypertension. Br. Heart J. 70(4), 366-370 (1993
17. Rubin LJ, Mendoza J, Hood M et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann. Intern. Med. 112(7), 485-491 (1990
18. Patterson JH, Adams KF Jr, Gheorghiade M et al. Acute hemodynamic effects of the prostacyclin analog 15AU81 in severe congestive heart failure. Am. J. Cardiol. 75(3), 26A-33A (1995
19. Mohler ER, Klugherz B, Goldman R, Kimmel SE, Wade M, Sehgal CM. Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication. Vasc. Med. 5(4), 231-237 (2000
20. Simonneau G, Barst RJ, Galie N et al.; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A double-Blind, randomized, placebocontrolled trial. Am. J. Respir. Crit. Care Med. 165(6), 800-804 (2002
21. Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M. Pharmacokinetics and steadystate bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J. Cardiovasc. Pharmacol. 44(2), 209-214 (2004
22. Gomberg-Maitland M, Tapson VF, Benza RL et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 172(12), 1586-1589 (2005
23. Hiremath J, Thanikachalam S, Parikh K et al.; TRUST Study Group. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: A placebo-Controlled trial. J. Heart Lung Transplant. 29(2), 137-149 (2010
24. Tapson VF, Gomberg-Maitland M, McLaughlin VV et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: A prospective, multicenter, open-Label, 12-Week trial. Chest 129(3), 683-688 (2006
25. Olschewski H, Simonneau G, Galiè N et al.; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N. Engl. J. Med. 347(5), 322-329 (2002
26. Sandifer BL, Brigham KL, Lawrence EC, Mottola D, Cuppels C, Parker RE. Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation. J. Appl. Physiol. 99(6), 2363-2368 (2005
27. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir. Med. 104(1), 9-21 (2010
28. Aronoff DM, Peres CM, Serezani CH et al. Synthetic prostacyclin analogs differentially regulate macrophage function via distinct analog-Receptor binding specificities. J. Immunol. 178(3), 1628-1634 (2007
29. Lai YJ, Pullamsetti SS, Dony E et al. Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 178(2), 188-196 (2008
30. Orie NN, Clapp LH. Role of prostanoid IP and EP receptors in mediating vasorelaxant responses to PGI2 analogues in rat tail artery: EVIDENCE for Gi/o modulation via EP3 receptors. Eur. J. Pharmacol. 654(3), 258-265 (2011
31. Falcetti E, Hall SM, Phillips PG et al. Smooth muscle proliferation and role of the prostacyclin (IP) receptor in idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 182(9), 1161-1170 (2010
32. Falcetti E, Flavell DM, Staels B, Tinker A, Haworth SG, Clapp LH. IP receptordependent activation of PPARgamma by stable prostacyclin analogues. Biochem. Biophys. Res. Commun. 360(4), 821-827 (2007
33. Morrell NW, Adnot S, Archer SL et al. Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54(Suppl. 1), S20-S31 (2009
34. Yang J, Li X, Al-Lamki RS et al. Smad-Dependent and smad-Independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo. Circ. Res. 107(2), 252-262 (2010
35. Cheng Y, Austin SC, Rocca B et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296(5567), 539-541 (2002
36. Junhui Z, Xingxiang W, Guosheng F, Yunpeng S, Furong Z, Junzhu C. Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. Respir. Med. 102(7), 1073-1079 (2008
37. Pendergrass SA, Hayes E, Farina G et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 5(8), e12106 (2010
38. Atsuta H, Uchiyama T, Kanai H et al. Effects of a stable prostacyclin analogue beraprost sodium on VEGF and PAI-1 gene expression in vascular smooth muscle cells. Int. J. Cardiol. 132(3), 411-418 (2009
39. Biscetti F, Gaetani E, Flex A et al. Peroxisome proliferator-Activated receptor alpha is crucial for iloprost-Induced in vivo angiogenesis and vascular endothelial growth factor upregulation. J. Vasc. Res. 46(2), 103-108 (2009
40. Fontana M, Olschewski H, Olschewski A, Schlüter KD. Treprostinil potentiates the positive inotropic effect of catecholamines in adult rat ventricular cardiomyocytes. Br. J. Pharmacol. 151(6), 779-786 (2007
41. Humbert M, Monti G, Brenot F et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am. J. Respir. Crit. Care Med. 151(5), 1628-1631 (1995
42. Katsushi H, Kazufumi N, Hideki F et al. Epoprostenol therapy decreases elevated circulating levels of monocyte chemoattractant protein-1 in patients with primary pulmonary hypertension. Circ. J. 68(3), 227-231 (2004
43. Pullamsetti SS, Savai R, Janssen W et al. Inflammation, immunological reaction and role of infection in pulmonary hypertension. Clin. Microbiol. Infect. 17(1), 7-14 (2011
44. Raychaudhuri B, Malur A, Bonfield TL et al. The prostacyclin analogue treprostinil blocks NFkappaB nuclear translocation in human alveolar macrophages. J. Biol. Chem. 277(36), 33344-33348 (2002
45. Zhou W, Hashimoto K, Goleniewska K et al. Prostaglandin I2 analogs inhibit proinflammatory cytokine production and T cell stimulatory function of dendritic cells. J. Immunol. 178(2), 702-710 (2007
46. Ikeda Y, Yonemitsu Y, Kataoka C et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary hypertension in rats. Am. J. Physiol. Heart Circ. Physiol. 283(5), H2021-H2028 (2002
47. Strassheim D, Riddle SR, Burke DL, Geraci MW, Stenmark KR. Prostacyclin inhibits IFN-Gamma-Stimulated cytokine expression by reduced recruitment of CBP/ p300 to STAT1 in a SOCS-1-Independent manner. J. Immunol. 183(11), 6981-6988 (2009
48. Centers for Disease Control and Prevention (CDC). Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension - seven sites, United States, 2003-2006. MMWR Morb. Mortal. Wkly Rep. 56(8), 170-172 (2007
49. Kallen AJ, Lederman E, Balaji A et al. Bloodstream infections in patients given treatment with intravenous prostanoids. Infect. Control Hosp. Epidemiol. 29(4), 342-349 (2008
50. Rich JD, Glassner C, Wade M et al. The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. Chest 141(1), 36-42 (2012
51. Voswinckel R, Enke B, Reichenberger F et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: Results from randomized controlled pilot studies. J. Am. Coll. Cardiol. 48(8), 1672-1681 (2006
52. Wade M, Baker FJ, Roscigno R, DellaMaestra W, Hunt TL, Lai AA. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J. Clin. Pharmacol. 44(1), 83-88 (2004
53. Channick RN, Olschewski H, Seeger W, Staub T, Voswinckel R, Rubin LJ. Safety and efficacy of inhaled treprostinil as add-On therapy to bosentan in pulmonary arterial hypertension. J. Am. Coll. Cardiol. 48(7), 1433-1437 (2006
54. McLaughlin VV, Gaine SP, Barst RJ et al.; Treprostinil Study Group. Efficacy and safety of treprostinil: AN epoprostenol analog for primary pulmonary hypertension. J. Cardiovasc. Pharmacol. 41(2), 293-299 (2003
55. Wade M, Baker FJ, Roscigno R et al. Pharmacokinetics of treprostinil sodium administered by 28-Day chronic continuous subcutaneous infusion. J. Clin. Pharmacol. 44(5), 503-509 (2004
56. McSwain CS, Benza R, Shapiro S et al. Dose proportionality of treprostinil sodium administered by continuous subcutaneous and intravenous infusion. J. Clin. Pharmacol. 48(1), 19-25 (2008
57. Olschewski H, Rohde B, Behr J et al. Pharmacodynamics and pharmacokinetics of inhaled iloprost, aerosolized by three different devices, in severe pulmonary hypertension. Chest 124(4), 1294-1304 (2003
58. Voswinckel R, Ghofrani HA, Grimminger F, Seeger W, Olschewski H. Inhaled treprostinil [corrected] for treatment of chronic pulmonary arterial hypertension. Ann. Intern. Med. 144(2), 149-150 (2006
59. Walkey AJ, Fein D, Horbowicz KJ, Farber HW. Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension. Pulm. Pharmacol. Ther. 24(4), 421-425 (2011
60. Tyvaso® (treprostinil) inhalation solution, full prescribing information - Revised 2/2011. United Therapeutics, Silver Spring, MD, USA (2011
61. Gotzkowsky SK, Dingemanse J, Lai A, Mottola D, Laliberte K. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J. Clin. Pharmacol. 50(7), 829-834 (2010
62. Wade M, Hunt TL, Lai AA. Effect of continuous subcutaneous treprostinil therapy on the pharmacodynamics and pharmacokinetics of warfarin. J. Cardiovasc. Pharmacol. 41(6), 908-915 (2003
63. Voswinckel R, Reichenberger F, Enke B et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm. Pharmacol. Ther. 21(5), 824-832 (2008
64. McLaughlin VV, Benza RL, Rubin LJ et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J. Am. Coll. Cardiol. 55(18), 1915-1922 (2010
65. Benza RL, Seeger W, McLaughlin VV et al. Long-Term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: The Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-Label extension. J. Heart Lung Transplant. 30(12), 1327-1333 (2011
66. Food and Drug Administration. Center for Drug Evaluation and Research. Medical Review - New Drug Application, NDA 22-387. US FDA, USA (2009
67. Simonneau G, Rubin LJ, Galiè N et al.; PACES Study Group. Addition of sildenafil to long-Term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial. Ann. Intern. Med. 149(8), 521-530 (2008
68. O'Callaghan DS, Savale L, Jais X et al. Evidence for the use of combination targeted therapeutic approaches for the management of pulmonary arterial hypertension. Respir. Med. 104 (Suppl. 1), S74-S80 (2010
69. Hoeper MM, Leuchte H, Halank M et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur. Respir. J. 28(4), 691-694 (2006
70. Galiè N, Hoeper MM, Humbert M et al.; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of ardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J. 30(20), 2493-2537 (2009
71. Galiè N, Humbert M, Vachiéry JL et al.; Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: A randomized, double-Blind, placebocontrolled trial. J. Am. Coll. Cardiol. 39(9), 1496-1502 (2002
72. Barst RJ, McGoon M, McLaughlin V et al.; Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol. 41(12), 2119-2125 (2003
73. Rubin L, Parikh K, Pulido T et al. FREEDOM-M: Efficacy and safety of oral treprostinil diethanolamine as monotherapy in patients with pulmonary arterial hypertension. Chest 140(4), abstract 1044 (2011
74. Voswinckel R, Reichenberger F, Gall H et al. Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. Pulm. Pharmacol. Ther. 22(1), 50-56 (2009
75. Olschewski H, Ghofrani A, Walmrath D et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am. J. Respir. Crit. Care Med. 160(2), 600-607 (1999
76. Dernaika TA, Beavin M, Kinasewitz GT. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 79(5), 377-382 (2010
77. Hegewald MJ, Elliott CG. Sustained improvement with iloprost in a COPD patient with severe pulmonary hypertension. Chest 135(2), 536-537 (2009
78. Tissières P, Nicod L, Barazzone-Argiroffo C, Rimensberger PC, Beghetti M. Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension. Ann. Thorac. Surg. 78(3), e48-E50 (2004)